Currently, the most widely used and successful CAR is the CD19-CAR, which recognizes the CD19 molecule expressed on the surface of B cells, thus can eliminate some B-cell-derived leukemias and lymphomas (5, 6), including complete response in nearly 90% of B-cell leukemia patients (5). The gene discussed is CD19; the disease is leukemia.